Command Palette

Search for a command to run...

Clinical Trials · NCT04426474

A Study of LY3502970 in Participants With Type 2 Diabetes

CompletedPhase 1Orforglipron (Approved)
Phase
Phase 1
Recruitment status
Completed
Sponsor
Eli Lilly and Company
Enrollment
68
Start date
Oct 2020
Locations
6 sites, United States, Germany
Primary endpoint
Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug
View Orforglipron compound reference